Lund, Sweden, 2015-04-20 10:12 CEST (GLOBE NEWSWIRE) --
Last Friday, EXINI Diagnostics AB and FUJIFILM RI Pharma arranged a BSI-seminar (Bone Scan Index) in the Alfred Nobel Auditorium at the Swedish Embassy in Tokyo. The event attracted executives from both pharmaceutical and CRO (Contract Research Organizations) industries.
The seminar demonstrated widespread benefits to be gained from using the imaging biomarker Bone Scan Index (BSI) in clinical workflow and in pharmaceutical clinical development.
“The imaging biomarker BSI adds clinical value and quantitative information to bone scans that makes it possible to follow treatment responses, and to make prognosis of disease outcomes”, explains Dr Kenichi Nakajima, Kanazawa University.
“BSI provides doctors treating prostate cancer with better information, rather than depending solely on PSA. BSI makes it possible to keep patients on therapy and prevent unnecessary drop-outs when PSA fails to provide accurate information by itself”, explains Professor Anders Bjartell, Head of Urology, Skåne University Hospital.
“EXINI boneBSI is the only available clinical solution to accurately provide the biomarker BSI in the US, the EU and in Japan. We are now actively searching for partners in the industry to expand the usage of BSI”, comments Magnus Aurell CEO, EXINI Diagnostics AB.
More on Bone Scan Index (BSI)
BSI is an imaging biomarker providing fast, accurate and quantifiable information to be used for diagnosis and stratification and the monitoring of treatment response. It also provides increased accuracy in prognoses involving patients suffering from skeletal metastases originating from prostate cancer.
Moreover, BSI has demonstrated its importance in the process of developing new drugs, thus proving itself just as important for clinical use as for the pharmaceutical industry.
EXINI boneBSI is the only software capable of extracting BSI-values for these purposes.
www.bonescanindex.org
www.exini.com/software/exini-bone-bsi/
For more information, please contact:
Magnus Aurell, CEO
Phone: +46 46 286 54 25
E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB (publ)
EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as cancer, coronary heart disease, dementia and Parkinson's disease. EXINI is listed on the stock market NASDAQ OMX First North and has about 1000 shareholders. Consensus acts as Certified Adviser.
________________________________________________________________________
EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden
Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com
